JP2007523088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523088A5 JP2007523088A5 JP2006553341A JP2006553341A JP2007523088A5 JP 2007523088 A5 JP2007523088 A5 JP 2007523088A5 JP 2006553341 A JP2006553341 A JP 2006553341A JP 2006553341 A JP2006553341 A JP 2006553341A JP 2007523088 A5 JP2007523088 A5 JP 2007523088A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antagonist
- cells
- viral
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 20
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 239000000556 agonist Substances 0.000 claims 12
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 claims 12
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 102000013264 Interleukin-23 Human genes 0.000 claims 9
- 230000003612 virological effect Effects 0.000 claims 9
- 230000027455 binding Effects 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 230000009385 viral infection Effects 0.000 claims 5
- 208000036142 Viral infection Diseases 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 241000712461 unidentified influenza virus Species 0.000 claims 4
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 claims 1
- 101710103840 Interleukin-12 receptor subunit beta-2 Proteins 0.000 claims 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 208000037798 influenza B Diseases 0.000 claims 1
- 208000037799 influenza C Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54570804P | 2004-02-17 | 2004-02-17 | |
| US60/545,708 | 2004-02-17 | ||
| PCT/US2005/004742 WO2005079837A1 (en) | 2004-02-17 | 2005-02-15 | Methods of modulating il-23 activity; related reagents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011261668A Division JP2012092117A (ja) | 2004-02-17 | 2011-11-30 | Ｉｌ−２３活性を調節する方法；関連する試薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007523088A JP2007523088A (ja) | 2007-08-16 |
| JP2007523088A5 true JP2007523088A5 (https=) | 2008-02-28 |
| JP4903061B2 JP4903061B2 (ja) | 2012-03-21 |
Family
ID=34886185
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553341A Expired - Fee Related JP4903061B2 (ja) | 2004-02-17 | 2005-02-15 | Ｉｌ−２３活性を調節する方法；関連する試薬 |
| JP2011261668A Withdrawn JP2012092117A (ja) | 2004-02-17 | 2011-11-30 | Ｉｌ−２３活性を調節する方法；関連する試薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011261668A Withdrawn JP2012092117A (ja) | 2004-02-17 | 2011-11-30 | Ｉｌ−２３活性を調節する方法；関連する試薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8263080B2 (https=) |
| EP (1) | EP1901768B1 (https=) |
| JP (2) | JP4903061B2 (https=) |
| CN (1) | CN1942201B (https=) |
| AT (1) | ATE533502T1 (https=) |
| AU (1) | AU2005215527B2 (https=) |
| BR (1) | BRPI0507794A (https=) |
| CA (1) | CA2556425A1 (https=) |
| NO (1) | NO20064194L (https=) |
| NZ (1) | NZ548897A (https=) |
| WO (1) | WO2005079837A1 (https=) |
| ZA (1) | ZA200606620B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7510709B2 (en) * | 2002-10-30 | 2009-03-31 | Genentech, Inc. | Method of treating inflammatory disease by inhibition of IL-17 production |
| AU2006265002B2 (en) | 2005-06-30 | 2012-09-20 | Centocor, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
| DE602006015830D1 (de) * | 2005-08-25 | 2010-09-09 | Lilly Co Eli | Anti-il-23-antikörper |
| SI1971366T1 (sl) | 2005-12-29 | 2014-10-30 | Janssen Biotech, Inc. | Humana protitelesa anti-il-23, sestavki, postopki in uporabe |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| JP2009540018A (ja) * | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| AU2008219684B2 (en) * | 2007-02-28 | 2014-04-17 | Merck Sharp & Dohme Corp. | Engineered anti-IL-23R antibodies |
| EP2220120A2 (en) | 2007-11-27 | 2010-08-25 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| SG10201608871XA (en) | 2008-05-05 | 2016-12-29 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| CA2759848C (en) * | 2009-05-05 | 2018-12-04 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
| US9301997B2 (en) | 2009-09-21 | 2016-04-05 | Peptinov Sas | Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides |
| PE20141162A1 (es) | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| EP4039275A1 (en) | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CN103837687A (zh) * | 2014-03-10 | 2014-06-04 | 青岛康立泰药业有限公司 | 使用具有白细胞介素-12受体的细胞检测重组人白细胞介素-12体外活性的方法及应用 |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| UA123624C2 (uk) | 2014-09-03 | 2021-05-05 | Бьорінґер Інґельхайм Інтернаціональ Ґмбх | Сполука, специфічна до іл-23а та фнп-альфа, та її застосування |
| CN107206081A (zh) | 2015-02-04 | 2017-09-26 | 勃林格殷格翰国际有限公司 | 治疗炎性疾病的方法 |
| KR101873499B1 (ko) * | 2015-02-10 | 2018-07-03 | 주식회사 원메디칼 | 혈관 질환 진단용 바이오 마커 및 이의 용도 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| WO2018218231A1 (en) * | 2017-05-25 | 2018-11-29 | The Broad Institute, Inc. | Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof |
| US20200147177A1 (en) * | 2017-07-17 | 2020-05-14 | Chu De Nantes - Centre Hospitalier Universitaire De Nantes | Interleukin 12 (il12) or derivative thereof for use in the treatment of secondary disease |
| CA3092551A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| KR102885113B1 (ko) | 2018-10-18 | 2025-11-13 | 머크 샤프 앤드 돔 엘엘씨 | 항-rsv 항체의 제제 및 그의 사용 방법 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| MA55149A (fr) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
| WO2020234834A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| US12577297B2 (en) | 2019-09-09 | 2026-03-17 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 antibody formulations |
| KR20230023663A (ko) | 2020-05-21 | 2023-02-17 | 얀센 바이오테크 인코포레이티드 | Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| US7422743B2 (en) * | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| CA2408571C (en) * | 2000-05-10 | 2014-04-29 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| AU2003243189B2 (en) * | 2002-05-01 | 2008-01-24 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat HIV infection and AIDS |
| US7510709B2 (en) * | 2002-10-30 | 2009-03-31 | Genentech, Inc. | Method of treating inflammatory disease by inhibition of IL-17 production |
| JP4902961B2 (ja) * | 2002-12-23 | 2012-03-21 | シェーリング コーポレイション | 哺乳動物サイトカインの用途；関連試薬 |
| WO2004060291A2 (en) * | 2002-12-31 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| US20040219150A1 (en) * | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| BRPI0408247A (pt) * | 2003-03-10 | 2006-03-01 | Schering Corp | usos de antagonistas e agonistas de il-23 e reagentes relacionados |
| CA2522007A1 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Methods of preventing or treating respiratory conditions |
| EP1623011B1 (en) * | 2003-05-09 | 2013-01-02 | Janssen Biotech, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
-
2005
- 2005-02-15 AU AU2005215527A patent/AU2005215527B2/en not_active Ceased
- 2005-02-15 CN CN2005800114552A patent/CN1942201B/zh not_active Expired - Fee Related
- 2005-02-15 EP EP05713576A patent/EP1901768B1/en not_active Expired - Lifetime
- 2005-02-15 WO PCT/US2005/004742 patent/WO2005079837A1/en not_active Ceased
- 2005-02-15 US US11/059,114 patent/US8263080B2/en active Active
- 2005-02-15 CA CA002556425A patent/CA2556425A1/en not_active Abandoned
- 2005-02-15 JP JP2006553341A patent/JP4903061B2/ja not_active Expired - Fee Related
- 2005-02-15 BR BRPI0507794-0A patent/BRPI0507794A/pt not_active IP Right Cessation
- 2005-02-15 AT AT05713576T patent/ATE533502T1/de active
- 2005-02-15 NZ NZ548897A patent/NZ548897A/xx not_active IP Right Cessation
-
2006
- 2006-08-08 ZA ZA200606620A patent/ZA200606620B/xx unknown
- 2006-09-15 NO NO20064194A patent/NO20064194L/no not_active Application Discontinuation
-
2011
- 2011-11-30 JP JP2011261668A patent/JP2012092117A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523088A5 (https=) | ||
| US20210349104A1 (en) | Viral serology assays | |
| Hamelin et al. | Human metapneumovirus: a new player among respiratory viruses | |
| US20230204568A1 (en) | Measuring trail by lateral flow immunoassay | |
| Hamelin et al. | Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease | |
| Rota et al. | Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York city in 2009 | |
| Boyoglu-Barnum et al. | Mutating the CX3C motif in the G protein should make a live respiratory syncytial virus vaccine safer and more effective | |
| Oliva et al. | Murine model for the study of influenza D virus | |
| Dakhama et al. | Common respiratory viruses in lower airways of patients with acute hypersensitivity pneumonitis | |
| EP4033248B1 (en) | System and method for analysis of mx1 and crp in blood | |
| US20220381780A1 (en) | Viral strain serology assays | |
| Malmo et al. | Cytokine profiles in human metapneumovirus infected children: identification of genes involved in the antiviral response and pathogenesis | |
| Vidaña et al. | Heterogeneous pathological outcomes after experimental pH1N1 influenza infection in ferrets correlate with viral replication and host immune responses in the lung | |
| JP2014518624A5 (https=) | ||
| Huang et al. | Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9 | |
| Schmidt et al. | Effect of mucosal adjuvant IL-1β on heterotypic immunity in a pig influenza model | |
| Long et al. | IL-17A plays a critical role in RSV infection in children and mice | |
| Leland | Parainfluenza and mumps viruses | |
| Wibawa et al. | Comparison of serological assays for detecting antibodies in ducks exposed to H5 subtype avian influenza virus | |
| Brand et al. | Biomarkers associated with vaccine-associated enhanced respiratory disease following influenza A virus infection in swine | |
| Takemae et al. | Experimental infection of pigs with H1 and H3 influenza A viruses of swine by using intranasal nebulization | |
| Yang et al. | Binding and entry of peste des petits ruminants virus into caprine endometrial epithelial cells profoundly affect early cellular gene expression | |
| TW202128749A (zh) | 辨識抗ｒｓ病毒之抗體、以及使用該抗體之免疫測定方法及免疫測定器具 | |
| Tut et al. | Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection | |
| Watson et al. | Isolation and characterisation of an H3N8 equine influenza virus in Australia, 2007 |